Company news

AbbVie Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

October 17, 2025

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

October 13, 2025

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

October 13, 2025

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

October 9, 2025

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

October 6, 2025

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

October 2, 2025

Natrelle® Awarded Supplier Agreement from Vizient

October 1, 2025

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

September 30, 2025

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

September 30, 2025

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

September 29, 2025

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

September 29, 2025

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

September 26, 2025

QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published

September 25, 2025

Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

September 25, 2025

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

September 23, 2025

AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta

September 15, 2025

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

September 9, 2025

AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 3, 2025

AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

September 2, 2025

AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work

August 31, 2025

RINVOQ® (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults

August 27, 2025

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

August 25, 2025

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

August 21, 2025

AbbVie Completes Acquisition of Capstan Therapeutics

August 19, 2025

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

August 12, 2025

Get Ready, JUVÉDERM® Day is Calling!

August 6, 2025

Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency

August 5, 2025

AbbVie Reports Second-Quarter 2025 Financial Results

July 31, 2025

AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

July 30, 2025

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

July 29, 2025

BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project

July 22, 2025

AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact

July 15, 2025

Refresh Releases First of its Kind Eye Drop for Dry Eyes

July 11, 2025

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

July 10, 2025

AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

July 10, 2025

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

June 30, 2025

U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

June 30, 2025

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

June 30, 2025

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

January 11, 2025

← Newer news releases

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.